全球酒精使用障碍市场：区域与国家分析与预测（2025-2035 年）

全球酒精使用障碍市场目前正处于生命週期的成长阶段。

这一阶段的特点是创新治疗方法的需求不断增长，酒精使用障碍被认可为重大公共卫生问题。个人化医疗的进步（根据个人基因图谱优化治疗方法）和新的、更有效和更有针对性的药物疗法的开发正在推动市场成长。此外，整合药物治疗和行为疗法的综合治疗模式的广泛采用也促进了市场扩张。此外，远端医疗和线上支援平台等数位健康技术的日益普及，正在改善酒精使用障碍治疗的可近性，特别是在服务欠缺地区。全球加强成瘾治疗医疗基础设施的运动也在不断发展，这有助于扩大治疗的范围和可用性。儘管存在这些机会，但治疗费用高昂和对成瘾的社会耻辱等挑战依然存在，这些挑战阻碍了治疗方法的广泛采用，特别是在开发中国家。儘管如此，随着透过公共卫生宣传活动提高认识和改善治疗途径，预计未来市场将进一步成长并进入更成熟的阶段。

影响

• 预计预测期内，对酒精使用障碍治疗的需求不断增长将推动全球市场的成长
• 标靶治疗的进步、认识和诊断的提高、临床管道的扩大、医疗保健基础设施的改善以及获得专门治疗的机会预计将成为推动市场发展的关键驱动力。

最新动态

• 研究活动：2025 年 5 月，Adial Pharmaceuticals, Inc. 宣布美国专利商标局已授予专利号 12,274,692，涵盖使用 AD04 治疗基因定义的患者群体中的酒精相关和阿片类药物相关疾病的创新方法。

本报告调查了全球酒精使用障碍市场，并总结了主要趋势、市场影响因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球酒精使用障碍市场：产业展望

• 市场概况与生态系统
• 市场趋势
• 酒精使用疾患的流行病学分析
  • 按地区
• 临床试验
  • 按阶段
  • 依赞助商类型
• 监管状况/合规性
  • 美国法律要求与框架
  • 欧盟法律要求和框架
  • 亚太地区的法律要求与框架
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

2. 全球酒精使用障碍市场（按地区）

• 北美洲
• 欧洲
• 亚太地区
  • 市场动态
  • 市场规模及预测

3. 全球酒精使用疾患市场：竞争基准化分析与公司简介

• 竞争格局
  • 各公司主要策略及发展
  • 重大进展分析
• 公司简介
  • Clearmind Medicine Inc.
  • Purdue Pharma LP
  • Psyence Biomedical
  • Eli Lilly and Company
  • Tempero Bio, Inc.
  • Nxera Pharma Co., Ltd.
  • Novo Nordisk A/S
  • Adial Pharmaceuticals
  • Alkermes
  • Lundbeck

第四章调查方法

Market Lifecycle Stage

The global alcohol use disorder market is currently in the growth stage of its lifecycle. This phase is characterized by a rising demand for innovative treatments and increased recognition of alcohol use disorder as a significant public health issue. The market is benefiting from advancements in personalized medicine, where treatments are tailored to individuals based on genetic profiles, as well as the development of new pharmacotherapies that offer more effective and targeted solutions. Additionally, the market is being driven by the growing integration of behavioral therapies with pharmacological treatments, creating more comprehensive and effective care models. Another key factor in the market's growth is the increasing adoption of digital health technologies, including telemedicine and online support platforms, which make alcohol use disorder treatments more accessible, especially in underserved regions. This is coupled with a global push for better addiction treatment infrastructure, expanding both the reach and availability of care. Despite these opportunities, challenges such as high treatment costs and social stigmas related to addiction still persist, especially in developing markets, potentially limiting the broader adoption of treatment solutions. However, as public health initiatives continue to promote awareness and access, the market is expected to grow further and move toward a more mature stage in the coming years.

Impact

• Increasing demand for alcohol use disorder therapies is anticipated to support the growth of the global alcohol use disorder market during the forecast period 2025-2035.
• The global alcohol use disorder market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.

Recent Developments

• Research Activities: In May 2025, Adial Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 12,274,692, covering an innovative method for treating alcohol-related and opioid-related disorders using AD04 in genetically defined patient populations.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Alcohol Use Disorder
• Improved Diagnostic Criteria and Screening Tools

Limitations:

• Limited Treatment Options for Specific Populations

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global alcohol use disorder market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Adial Pharmaceutical, Inc., have been involved in the development of therapies for alcohol use disorder.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

• Clearmind Medicine Inc.
• Purdue Pharma L.P.
• Psyence Biomedical
• Eli Lilly and Company
• Tempero Bio, Inc.
• Nxera Pharma Co., Ltd.
• Novo Nordisk A/S
• Adial Pharmaceuticals
• Alkermes
• Lundbeck

Table of Contents

Executive Summary

Scope of Study

1. Global Alcohol Use Disorder Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Alcohol Use Disorder
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Alcohol Use Disorder Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Alcohol Use Disorder Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Alcohol Use Disorder Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Alcohol Use Disorder Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Alcohol Use Disorder Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Clearmind Medicine Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Purdue Pharma L.P.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Psyence Biomedical
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Eli Lilly and Company
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Tempero Bio, Inc.
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Nxera Pharma Co., Ltd.
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Novo Nordisk A/S
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View
  • 3.2.8 Adial Pharmaceuticals
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers/End Users
    • 3.2.8.4 Analyst View
  • 3.2.9 Alkermes
    • 3.2.9.1 Company Overview
    • 3.2.9.2 Product Portfolio
    • 3.2.9.3 Target Customers/End Users
    • 3.2.9.4 Analyst View
  • 3.2.10 Lundbeck
    • 3.2.10.1 Company Overview
    • 3.2.10.2 Product Portfolio
    • 3.2.10.3 Target Customers/End Users
    • 3.2.10.4 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Alcohol Use Disorder Market, Market Overview
• Figure: Global Alcohol Use Disorder Market Coverage
• Figure: Global Alcohol Use Disorder Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Alcohol Use Disorder Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table: Global Alcohol Use Disorder Market, Regulatory Scenario
• Table: Global Alcohol Use Disorder Market Dynamics, Impact Analysis